To view this email as a web page, click here.

 
 
Continuing the innovation journey
In recognition of the first anniversary of our Innovation column, Drs. Steve Xu and William Ju reflect on the range of topics covered throughout the year and highlight what's to come.
 
ADVERTISEMENT
 
 
Innovation dispatches from the AAD
The Dermatology Innovation Forum, a one-day pre-AAD meeting, gives physicians a frontline seat to founder stories, new innovations and major advances happening currently in dermatology. Here are some of the highlights from the 2019 DIF conference.
 
Novel dermatology drugs approved in 2018
In many ways, 2018 was a banner year for new novel drug approvals with 59 drugs approved by the FDA’s Center for Drug Evaluation and Research (CDER). Learn about the innovative drugs that were approved for dermatological indications in this article.
 
Connect with us on Twitter and Facebook for daily updates.
 
ADVERTISEMENT
Adopting a multidisciplinary approach for melasma
In this Dermatology Times podcast, featured physician Seemal Desai, MD, FAAD, details his range of therapeutic combinations and methods to guide patients in maximizing adherence and minimizing relapse. Listen to the podcast now.
 
From our Latest Issue
 
Dermatology Times cover
Self-esteem and melasma
 
New rosacea therapies show promise
 
Dermatologist discusses permanent eyeliner, microblading
 
ADVERTISEMENT
Do you know an individual whose revolutionary ideas have refined the practice of dermatology?
Help us identify physicians and researchers in the field of dermatology whose dedication to the field has resulted in successful innovations and has inspired, informed, or improved the treatment of patients with skin disorders. Nominate a leader today for the 2020 Giants of DermatologyTM recognition program.
 
JOB OPPORTUNITIES
 
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.